Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

320 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-09-30

Study Completion Date

2018-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hepatocellular carcinoma (HCC) is one of the most common solid cancers worldwide, and chronic hepatitis B virus (HBV) infection is the most common etiology of HCC in Asia. Transarterial chemoembolization (TACE) is the standard treatment for patients with unresectable HCC in the BCLC intermediate stage, but the HCC recurrence rates and long-term mortality rates are quite high. These intermediate-staged HCC patients usually need repeated TACE due to tumor recurrence, and they may die of HCC progression or liver decompensation after repeated TACE. Improved liver function and decreased liver disease progression due to oral antiviral therapy have been proven to be effective for chronic hepatitis B, and oral antiviral therapy may keep better liver reserve and provide better chance for HCC patients received TACE. In addition, chronic HBV infection is one of the most important factors for HCC development, and antiviral therapy can improve the outcomes after curative treatment. However, the evidence of improving outcomes of HCC patients underwent TACE by oral antiviral therapy is lacking. Moreover, Tenofovir Disoproxil Fumarate (TDF) is one of the most potent oral antiviral agents, and its safety and very low long-term viral resistance rate have been also reported. There is no study to evaluate the impacts of TDF for HBV-related HCC patients underwent TACE. Until now, routine antiviral therapy for HBV-related HCC patients underwent TACE has still not been recommended by current guidelines. The hypothesis of this study is that a potent oral antiviral therapy for patients with HBV-related HCC patients receiving TACE improve patients' outcomes

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Tenofovir Alafenamide(TAF) Reduces the Risk of Hepatocellular Carcinoma(HCC) Recurrence

NCT04290936

HCC Patients After Curative Treatment With Low HBV Viral Load

UNKNOWN PHASE4

Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC

NCT02650271

Hepatocellular Carcinoma

COMPLETED PHASE3

Sorafenib and Transarterial Chemoembolization for Hepatocellular Carcinoma

NCT00768937

Hepatocellular Carcinoma

COMPLETED PHASE1/PHASE2

Prompt Or Watchful Monitoring for Hepatitis B Virus Related Hepatocellular Carcinoma Without Elevated viRal Load

NCT02308319

Carcinoma, Hepatocellular

UNKNOWN PHASE4

Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication

NCT01894269

Hepatocellular Carcinoma

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is randomized double-blind placebo-controlled trial that will be conducted in referral teaching hospitals in Taiwan. This trial will recruit 320 patients fulfilling all of the following criteria: patients more than 20 years old, HCCs diagnosed by AASLD image criteria or pathology, medium-sized HCCs in BCLC intermediate stage and not more than 5 cm in maximum diameter and not more than 5 tumors that TACE is indicated, chronic HBV carrier (HBsAg+) with detectable HBV DNA in blood, ECOG performance status (PST) 0-2, Child-Pugh score ≦7, serum bilirubin \< 2 mg/dL and prothrombin time (PT) prolongation \< 3 seconds, and willingness to adhere to treatment and follow-up plans. Patients are ineligible if they have any of the following exclusion criteria: any vascular invasion by tumors, extra-hepatic metastasis, concurrent any other malignancy, concomitant immunosuppressive therapy, previous any HCC treatment, previous or current any antiviral therapy for HBV, concomitant other therapies for HCC except TACE, liver cirrhosis with severe gastroesophageal varices (EVF3 or with red color sign), poorly-controlled ascites or hepatic encephalopathy, contraindication for invasive procedures such as recent gastrointestinal bleeding or cerebral hemorrhage, contraindication to TACE such as allergy to contrast, pregnancy, sepsis, etc., chronic renal failure with eGFR \< 60, concurrent any other chronic viral hepatitis with HCV, HDV, or HIV). The Primary endpoints of this study will be 1-, 3-year overall survival, and the secondary endpoints of this study will be time to tumor progression and time to liver decompensation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Hepatitis B Hepatocellular Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tenofovir treatment

Start to administer Tenofovir treatment 300mg PO QD within 2 weeks after the 1st TACE. Maximum duration of tenofovir treatment: 3 years.

Group Type ACTIVE_COMPARATOR

Tenofovir

Intervention Type DRUG

Administer Tenofovir to HCC patients who are indicated for TACE after randomization

Placebo

Start to administer placebo 1 Tab PO QD within 2 weeks after the 1st TACE. Maximum duration of tenofovir treatment: 3 years.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administer Placebo to HCC patients who are indicated for TACE after randomization

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tenofovir

Administer Tenofovir to HCC patients who are indicated for TACE after randomization

Intervention Type DRUG

Placebo

Administer Placebo to HCC patients who are indicated for TACE after randomization

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Viread

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. more than 20 years old
2. HCCs diagnosed by AASLD image criteria or pathology
3. Intermediate-stage HCCs that TACE is indicated
4. chronic HBV carrier with detectable HBV DNA in blood
5. ECOG performance status (PST) 0-2
6. Child-Pugh score ≦7
7. serum bilirubin \< 2 mg/dL
8. prothrombin time prolongation \< 3 seconds
9. willingness to adhere to treatment and follow-up plans -

Exclusion Criteria

1. any vascular invasion by tumors
2. extra-hepatic metastasis
3. concurrent any other malignancy
4. concomitant immunosuppressive therapy
5. HCC recurrence within 2 years of previous curative treatment
6. antiviral therapy for chronic hepatitis B within 6 months before HCC diagnosis
7. concomitant other therapies for HCC except TACE
8. liver cirrhosis with severe gastroesophageal varices (EVF3 or with red color sign), poorly-controlled ascites or hepatic encephalopathy
9. contraindication for invasive procedures such as recent gastrointestinal bleeding or cerebral hemorrhage
10. contraindication to TACE such as allergy to contrast, pregnancy, sepsis, etc.
11. chronic renal failure with eGFR \< 60
12. concurrent any other chronic viral hepatitis with HCV, HDV, or HIV) -

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No